dapagliflozin

Description: Dapagliflozin (formerly known as BMS-512148; trade names Farxiga in the US and Forxiga in the EU) is a potent and selective hSGLT2 (sodium-glucose transport proteins) inhibitor with anti-diabetic activity. It inhibits hSGLT2 with an EC50 of 1.1 nM, and exhibits1200-fold selectivity over hSGLT1. Dapagliflozin was approved in 2012 by FDA for the treatment of type 2 diabetes. Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter mechanism causes blood glucose to be eliminated through the urine.

References: J Med Chem. 2008 Mar 13; 51(5):1145-9; Diabetes. 2008 Jun; 57(6):1723-9.

Related CAS#: 960404-48-2 Dapagliflozin (2S)-1, 2-propanediol, hydrate is the S-enantiomer of Dapagliflozin 1, 2-propanediol, hydrate; 1204219-80-6 (Dapagliflozin D5)